# Understanding Hemophilia A and B Drug Dosage Administration Patterns

> **NCT03248141** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 11 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** Hemophilia B standard half-life
- **DRUG:** Hemophilia B extended half-life
- **DRUG:** Hemophilia A standard half-life
- **DRUG:** Hemophilia A extended half-life

## Key facts

- **NCT ID:** NCT03248141
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-01
- **Primary completion:** 2018-03-14
- **Final completion:** 2018-03-14
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. See details in Description section.
- **Last updated:** 2019-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03248141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03248141, "Understanding Hemophilia A and B Drug Dosage Administration Patterns". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03248141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*